Literature DB >> 26912389

A polyethylenimine functionalized porous/hollow nanoworm as a drug delivery system and a bioimaging agent.

Xiao Sun1, Chuanjie Cai2, Qian Wang3, Dongqing Cai1, Junchao Qian4, Yu Chi2, Kang Zheng5, Xin Zhang3, Guilong Zhang2, Kai Zhong4, Zhengyan Wu1.   

Abstract

A wormstructured and nanosized porous/hollow polyethyleneimine (PEI) functionalized Gd2O3/Fe3O4 composite was fabricated as a drug carrier and a bioimaging agent. The effect of PEI's chain length on the size and morphology of the nanoworm was investigated and the results indicated that the nanoworm modified with PEI (10,000 molecular weight) (designated as p-nanoworm) possessed a suitable size and a porous/hollow structure. Meanwhile, the p-nanoworm could effectively prevent the leakage of Gd ions under different pH conditions because of plenty of amino groups on their surface. Compared with contrast agents of clinical use, the p-nanoworm displayed MR enhancement with a high r1 relaxivity of 5.58 s(-1) mM(-1) per gadolinium atom. Cisplatin (CDDP), a clinical anticancer drug, could be easily loaded into the pores and lumen of the p-nanoworm (p-nanoworm-CDDP) and also controllably released by adjusting the pH value. Cell assay suggested that the p-nanoworm possessed satisfactory biocompatibility and meanwhile could promote CDDP uptake of HeLa cells and enhance the inhibition effect on HeLa cells. In addition, p-nanoworm-CDDP showed a negligible cytotoxicity on normal human cells, indicating that the side effect of CDDP is reduced. Thus, the p-nanoworm could have a potential application for the diagnosis and therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26912389     DOI: 10.1039/c5cp07933k

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  1 in total

1.  Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy.

Authors:  Ting Tang; Xiao Sun; Xuedong Xu; Yifeng Bian; Xiaojie Ma; Ning Chen
Journal:  RSC Adv       Date:  2019-01-18       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.